POPULATION PHARMACOKINETICS OF AMIKACIN IN INTENSIVE-CARE UNIT PATIENTS STUDIED BY NPEM ALGORITHM

被引:16
|
作者
DEBORD, J
PESSIS, C
VOULTOURY, JC
MARQUET, P
LOTFI, H
MERLE, L
LACHSATRE, G
机构
[1] HOP DUPUYTREN,SERV PHARMACOL TOXICOL,F-87042 LIMOGES,FRANCE
[2] HOP DUPUYTREN,SERV REANIMAT POLYVALENTE,F-87042 LIMOGES,FRANCE
[3] FAC PHARM LIMOGES,TOXICOL LAB,F-87025 LIMOGES,FRANCE
关键词
AMIKACIN; POPULATION PHARMACOKINETICS; NPEM ALGORITHM; BAYESIAN ESTIMATION; PREDICTIVE PERFORMANCE;
D O I
10.1111/j.1472-8206.1995.tb00266.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The population pharmacokinetics of amikacin was studied in 40 intensive care unit patients (212 plasma concentrations) by NPEM algorithm using a one-compartment model. The population was best characterized by the following pharmacokinetic parameters: renal clearance relative to creatinine clearance (C-s = 0.96 +/- 0.33), and either the total volume of distribution (V-d = 23.9 +/- 7.01) or the volume of distribution relative to body weight (V-s = 0.36 +/- 0.10 l.kg(-1). The volume of distribution was increased with respect to the usual value of 0.25 l.kg(-1). The statistical distribution of these pharmacokinetic parameters was approximately gaussian, with no significant correlation between volume of distribution and clearance. The medians and standard deviations of C-s and V-s were used as reference population values to estimate the pharmacokinetics of amikacin in a second group of 29 patients by the bayesian method, with two blood samples per patient. For each patient, the fitted parameters were able to predict the plasma concentrations of amikacin during the next 72 h with no significant bias and good precision (2.9 mg.l(-1) for peaks and 0.5 mg.l(-1) for troughs). This study confirms the ability of the NPEM algorithm to provide reference population values for use in bayesian monitoring of aminoglycoside therapy.
引用
收藏
页码:57 / 61
页数:5
相关论文
共 50 条
  • [1] Population pharmacokinetics of amikacin in geriatric patients studied with the NPEM-2 algorithm
    Debord, J
    Charmes, JP
    Marquet, P
    Merle, L
    Lachatre, G
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 1997, 35 (01) : 24 - 27
  • [2] POPULATION PHARMACOKINETIC PARAMETERS FOR BAYESIAN MONITORING OF AMIKACIN THERAPY IN INTENSIVE-CARE UNIT PATIENTS
    DEBORD, J
    VOULTOURY, JC
    LACHATRE, G
    GAY, C
    FAVEREAU, JP
    GAY, R
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1992, 43 (04) : 435 - 436
  • [3] Influence of Clinical Diagnosis in the Population Pharmacokinetics of Amikacin in Intensive Care Unit Patients
    Silvia Romano
    M. del Mar Fdez. de Gatta
    Victoria Calvo
    Eugenia Mendez
    Alfonso Domínguez-Gil
    José M. Lanao
    Clinical Drug Investigation, 1998, 15 : 435 - 444
  • [4] DETERMINATION OF PLASMA-CONCENTRATIONS OF AMIKACIN IN PATIENTS OF AN INTENSIVE-CARE UNIT
    PIMENTEL, FL
    ABELHA, F
    TRIGO, MA
    SA, LV
    MENEZES, MR
    JOURNAL OF CHEMOTHERAPY, 1995, 7 (01) : 45 - 49
  • [5] ONCE-DAILY DOSING OF AMIKACIN IN INTENSIVE-CARE UNIT
    BEAUCAIRE, G
    SANTRE, C
    MEDECINE ET MALADIES INFECTIEUSES, 1993, 23 : 67 - 74
  • [6] Population pharmacokinetics of cefotaxime in intensive care patients
    Swartling, Maria
    Smekal, Anna-Karin
    Furebring, Mia
    Lipcsey, Miklos
    Jonsson, Siv
    Nielsen, Elisabet I.
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2022, 78 (02) : 251 - 258
  • [7] Population pharmacokinetics of cefotaxime in intensive care patients
    Maria Swartling
    Anna-Karin Smekal
    Mia Furebring
    Miklos Lipcsey
    Siv Jönsson
    Elisabet I. Nielsen
    European Journal of Clinical Pharmacology, 2022, 78 : 251 - 258
  • [8] Altered Micafungin Pharmacokinetics in Intensive Care Unit Patients
    Lempers, Vincent J.
    Schouten, Jeroen A.
    Hunfeld, Nicole G.
    Colbers, Angela
    van Leeuwen, Henk J.
    Burger, David M.
    Verweij, Paul E.
    Pickkers, Peter
    Bruggemann, Roger J.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2015, 59 (08) : 4403 - 4409
  • [9] Optimising the dose of clonidine to achieve sedation in intensive care unit patients with population pharmacokinetics
    Cloesmeijer, Michael E.
    van den Oever, Huub L. A.
    Mathot, Ron A. A.
    Zeeman, Marieke
    Kruisdijk-Gerritsen, Arriette
    Bles, Carmen M. A.
    Nassikovker, Polina
    de Meijer, Arthur R.
    van Steveninck, Fred L.
    Arbouw, Maurits E. L.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2020, 86 (08) : 1620 - 1631
  • [10] Population pharmacokinetics of amikacin in patients with pediatric cystic fibrosis
    Caceres Guido, Paulo
    Perez, Mariel
    Halac, Alicia
    Ferrari, Mariela
    Ibarra, Manuel
    Licciardone, Nieves
    Castanos, Claudio
    Gravina, Luis P.
    Jimenez, Cristina
    Garcia Bournissen, Facundo
    Schaiquevich, Paula
    PEDIATRIC PULMONOLOGY, 2019, 54 (11) : 1801 - 1810